JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Investigating the role of KARS in lung adenocarcinoma via single-cell RNA sequencing

  • 0Department of Radiology, Liuzhou Traditional Chinese Medicine Hospital, No. 6, Honghu Road, Liuzhou, 545001, Guangxi, China.
Discover Oncology +

|

December 3, 2024

|

December 3, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

KARS expression is elevated in lung adenocarcinoma (LUAD), correlating with tumor progression and immune microenvironment interactions. This highlights KARS as a potential prognostic biomarker and therapeutic target for LUAD.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genomics

Background

  • Lung adenocarcinoma (LUAD) is a leading cause of cancer mortality.
  • LUAD exhibits significant molecular diversity.
  • KARS (a specific gene/protein) role in LUAD is under investigation.

Purpose Of The Study

  • Examine KARS expression and function in LUAD cell populations.
  • Identify KARS's prognostic value in LUAD.
  • Explore KARS's therapeutic implications for LUAD.

Main Methods

  • Utilized single-cell RNA sequencing (scRNA-seq) data from TCGA, GTEx, and GEO.
  • Analyzed KARS expression association with clinicopathological features and overall survival (OS).
  • Verified KARS expression using in vitro RT-PCR.

Main Results

  • KARS expression is significantly elevated in LUAD tissues compared to normal controls.
  • Increased KARS copy number correlates with its overexpression, genetic mutations, and higher mutational load.
  • KARS upregulation is linked to LUAD progression and modulates the tumor immune microenvironment.

Conclusions

  • KARS shows potential as a prognostic biomarker for LUAD.
  • KARS may be a viable therapeutic target for LUAD intervention.
  • Further research into KARS-targeting therapies for LUAD is warranted.

Keywords: